Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies
Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals
Scientific Process
“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says
Reviewers Note Major Flaws In Design Of Burzynski’s Trials
Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”
Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field
- The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer. - Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish
